Alert: Beware of new phone scam attempting to obtain personal information.
COVID-19: Get the latest updates, safety precautions, or learn how to schedule a video or in-person visit.

If you have a fever, cough or other symptoms of possible infection, notify us when you schedule an appointment and before you arrive. If you’re having a medical emergency, call 911. Upon arrival, everyone will receive a symptom and temperature check. Anyone with an elevated temperature will be connected with appropriate care.

Melanoma 

  • A091802: Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
  • S1801: Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery
  • EA6134: Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

  • S1616: A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1 or Anti-PD-L1 Agent

For more information, contact Lauren Key, 360-788-8238